Abstract：
BACKGROUND: The Institute of Hematology and Transfusion Medicine (IHTM) in Warsaw has produced autologous serum eye drops (ASEDs) for the treatment of Dry Eye Syndrome (DES) since 1991. In 2019, IHTM introduced allogeneic tears (alloSEDs) for patients on long-term treatment.
METHODS: 114 patients who applied alloSEDs were included in the study.They were asked to complete the OSDI questionnaire before and after using ASEDs and 100 units of alloSEDs drops from each donation. The OSDI index rates DES severity (0 no symptoms; 100 severe). We also compared the content of IL-1β, IL-2, IL- 6, IL-10 and VEGF in ASEDs (38 samples) and alloSEDs (15 serum samples). The study data covered the 2019-2022 period.
RESULTS: 114 patients participated in the study. We compared the the effectiveness of ASEDs and alloSEDs. The average, OSDI dropped from 68.42 ± 5,86 (before application) to 51.05 ± 19,06 (after application). Data from the questionnaires (prepared at IHTM) completed and returned (41/114) present the most common indications for the use of serum drops, including DES with no underlying disease, DES secondary to GvHD (Graft versus Host Disease), Sjögren\'s Syndrome (SS). The study reported higher cytokine levels associated with disease entities such as SS. After application of drops with high cytokine levels, patients reported adverse reactions such as sand under the eyelids, impaired visual acuity, and worse eye lubrication.
CONCLUSIONS: AlloSEDs with acceptably low values of pro-inflammatory cytokines and sufficiently high levels of VEGF growth factor may contribute to alleviation of inflammatory eye symptoms.
METHODS: 114 patients who applied alloSEDs were included in the study.They were asked to complete the OSDI questionnaire before and after using ASEDs and 100 units of alloSEDs drops from each donation. The OSDI index rates DES severity (0 no symptoms; 100 severe). We also compared the content of IL-1β, IL-2, IL- 6, IL-10 and VEGF in ASEDs (38 samples) and alloSEDs (15 serum samples). The study data covered the 2019-2022 period.
RESULTS: 114 patients participated in the study. We compared the the effectiveness of ASEDs and alloSEDs. The average, OSDI dropped from 68.42 ± 5,86 (before application) to 51.05 ± 19,06 (after application). Data from the questionnaires (prepared at IHTM) completed and returned (41/114) present the most common indications for the use of serum drops, including DES with no underlying disease, DES secondary to GvHD (Graft versus Host Disease), Sjögren\'s Syndrome (SS). The study reported higher cytokine levels associated with disease entities such as SS. After application of drops with high cytokine levels, patients reported adverse reactions such as sand under the eyelids, impaired visual acuity, and worse eye lubrication.
CONCLUSIONS: AlloSEDs with acceptably low values of pro-inflammatory cytokines and sufficiently high levels of VEGF growth factor may contribute to alleviation of inflammatory eye symptoms.
摘要：
背景：华沙的血液学和输血医学研究所（IHTM）自1991年以来生产了用于治疗干眼综合征（DES）的自体血清滴眼液（ASEDs）。2019年，IHTM为接受长期治疗的患者引入了同种异体眼泪（alloSED）。
方法：114例应用alloSED的患者纳入研究。他们被要求在使用ASED和每次捐赠的100单位alloSED滴剂之前和之后完成OSDI问卷。OSDI指数评估DES严重程度(0没有症状;100严重)。我们还比较了IL-1β的含量，ASED(38个样品)和alloSED(15个血清样品)中的IL-2、IL-6、IL-10和VEGF。研究数据涵盖2019-2022年期间。
结果：114名患者参与了这项研究。我们比较了ASED和alloSED的有效性。平均,OSDI从68.42±5,86(应用前)下降到51.05±19,06(应用后)。来自完成和返回的问卷（在IHTM准备）的数据（41/114）显示了使用血清滴剂的最常见适应症，包括没有潜在疾病的DES，继发于GvHD（移植物抗宿主病）的DES，干燥综合征（SS）。该研究报告了与疾病实体如SS相关的较高细胞因子水平。应用高细胞因子水平的滴剂后，患者报告不良反应，如眼睑下的沙子，视力受损，和更糟糕的眼睛润滑。
结论：具有可接受的低促炎细胞因子值和足够高水平的VEGF生长因子的AlloSED可能有助于减轻炎症性眼部症状。
方法：114例应用alloSED的患者纳入研究。他们被要求在使用ASED和每次捐赠的100单位alloSED滴剂之前和之后完成OSDI问卷。OSDI指数评估DES严重程度(0没有症状;100严重)。我们还比较了IL-1β的含量，ASED(38个样品)和alloSED(15个血清样品)中的IL-2、IL-6、IL-10和VEGF。研究数据涵盖2019-2022年期间。
结果：114名患者参与了这项研究。我们比较了ASED和alloSED的有效性。平均,OSDI从68.42±5,86(应用前)下降到51.05±19,06(应用后)。来自完成和返回的问卷（在IHTM准备）的数据（41/114）显示了使用血清滴剂的最常见适应症，包括没有潜在疾病的DES，继发于GvHD（移植物抗宿主病）的DES，干燥综合征（SS）。该研究报告了与疾病实体如SS相关的较高细胞因子水平。应用高细胞因子水平的滴剂后，患者报告不良反应，如眼睑下的沙子，视力受损，和更糟糕的眼睛润滑。
结论：具有可接受的低促炎细胞因子值和足够高水平的VEGF生长因子的AlloSED可能有助于减轻炎症性眼部症状。
